Messias Bruno Amantini, Franchi Bárbara Freitas, Pontes Pedro Henrique, Barbosa Daniel Átila DE Andrade Medeiros, Viana César Augusto Sanita
General Surgery Service, Carapicuíba General Hospital, Carapicuíba, SP, Brazil.
Medical School, São Camilo University Center, São Paulo, SP, Brazil.
Rev Col Bras Cir. 2018;45(2):e1609. doi: 10.1590/0100-6991e-20181609. Epub 2018 May 24.
Clostridium difficile infection is a common complication following intestinal dysbiosis caused by abusive antibiotic use. It presents medical importance due to the high rates of recurrence and morbidity. Fecal microbiota transplantation is an effective alternative for the treatment of recurrent and refractory C. difficile infection and consists of introducing the intestinal microbiota from a healthy donor into a patient with this infection. The exact physiological mechanism by which fecal microbiota transplantation alters the intestinal microbiota is not well established, but it is clear that it restores the diversity and structure of the microbiota by promoting increased resistance to colonization by C. difficile. Several routes of transplant administration are being studied and used according to the advantages presented. All forms of application had a high cure rate, and the colonoscopic route was the most used. No relevant complications and adverse events have been documented, and the cost-effectiveness over conventional treatment has proven advantageous. Despite its efficacy, it is not commonly used as initial therapy, and more studies are needed to establish this therapy as the first option in case of refractory and recurrent Clostridium difficileinfection.
艰难梭菌感染是滥用抗生素导致肠道生态失调后的常见并发症。由于其高复发率和发病率,具有医学重要性。粪便微生物群移植是治疗复发性和难治性艰难梭菌感染的有效替代方法,包括将健康供体的肠道微生物群引入患有这种感染的患者体内。粪便微生物群移植改变肠道微生物群的确切生理机制尚未完全明确,但很明显,它通过增强对艰难梭菌定植的抵抗力来恢复微生物群的多样性和结构。根据所呈现的优势,正在研究和使用几种移植给药途径。所有应用形式的治愈率都很高,结肠镜途径是最常用的。尚未记录到相关并发症和不良事件,并且已证明其相对于传统治疗的成本效益具有优势。尽管其疗效显著,但它并不常用作初始治疗方法,需要更多研究将这种疗法确立为难治性和复发性艰难梭菌感染的首选方案。